Spruce Biosciences Ownership
| SPRB Stock | USD 0.48 0.01 2.04% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 41.2 M | Current Value 41.3 M | Avarage Shares Outstanding 26.6 M | Quarterly Volatility 10.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Spruce |
Spruce Stock Ownership Analysis
About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Spruce Biosciences recorded a loss per share of 0.95. The entity had not issued any dividends in recent years. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California. Spruce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Spruce Biosciences contact MPH MD at 415 655 4168 or learn more at https://www.sprucebiosciences.com.Besides selling stocks to institutional investors, Spruce Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Spruce Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Spruce Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Spruce Biosciences Quarterly Liabilities And Stockholders Equity |
|
About 8.0% of Spruce Biosciences are currently held by insiders. Unlike Spruce Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Spruce Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Spruce Biosciences' insider trades
Spruce Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Spruce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Spruce Biosciences backward and forwards among themselves. Spruce Biosciences' institutional investor refers to the entity that pools money to purchase Spruce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 131.9 K | Blackrock Inc | 2024-06-30 | 124.7 K | Bridgeway Capital Management, Llc | 2024-06-30 | 85 K | Citadel Advisors Llc | 2024-06-30 | 84.7 K | Superstring Capital Management Lp | 2024-06-30 | 78 K | Lion Point Capital, Lp | 2024-09-30 | 75 K | Northern Trust Corp | 2024-09-30 | 74.9 K | State Street Corp | 2024-06-30 | 64.4 K | Two Sigma Advisers, Llc | 2024-06-30 | 45.7 K | Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | The Carlyle Group Inc | 2024-06-30 | 2.9 M |
Spruce Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spruce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spruce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spruce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spruce Biosciences Outstanding Bonds
Spruce Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spruce Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spruce bonds can be classified according to their maturity, which is the date when Spruce Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
| SPR 9375 30 NOV 29 Corp BondUS85205TAN00 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SPRINT P 7625 Corp BondUS85207UAK16 | View | |
| Sprint 7625 percent Corp BondUS85207UAJ43 | View | |
| SPRINT NEXTEL P Corp BondUS85208NAE04 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.